HOME >> BIOLOGY >> NEWS
Dengue and other hemorrhagic fevers: Towards a first potential treatment

Globally, 60 to 100 million people are hit by Dengue, a viral disease transmitted by mosquitoes of the genus Aedes. The most severe form of this disease, which causes blood loss, can lead to a fatal shock-like state (Dengue Shock Syndrome) with or without associated haemorrhage, and is currently increasing in tropical countries. The pathological mechanisms of Dengue are still unknown and it has not been possible to produce any treatment or vaccine. The only current prevention method is vector control.

This context brought IRD immunology and virology specialists and their research partners (1) to focus on these little-known biological mechanisms that are set into operation on infection by the virus, responsible for increasing the permeability of vascular wall endothelial cells and hence blood loss. The researchers found evidence of the role played by particular enzymes, metalloproteinases, in the occurrence of this leakage.

Low concentrations of these enzymes are present naturally in the organism, and they are involved in the reconfiguration of organ tissues during human embryonic development or tissue repair, but also in the development of certain cancers. They attack specifically the intercellular cement that binds the vascular walls. The research team demonstrated, in vitro, that Dengue-virus infection of certain targeted cells of the immune system (the dendritic cells) triggered an inflammatory reaction, stimulating these same target cells to overproduce metalloproteinases (gelatinolytic matrix metalloproteinases MMP-9) and secrete them into the cellular supernatant (2). The quantity of enzyme produced therefore appears to be proportional to the concentration of viral particles present.

To verify that the metalloproteinases were the only agents responsible for the increased vascular permeability, the researchers performed tests on cell cultures of endothelial tissue, of the same type as that of the blood vessel walls. The supernatant
'"/>

Contact: Guillaume-Signoret Marie
fichesactu@paris.ird.fr
33-014-803-7607
Institut de Recherche Pour le Dveloppement
22-Dec-2006


Page: 1 2

Related biology news :

1. Dengue virus reveals its circular secret
2. Study finds gender differences in renal and other genes contributing to blood pressure
3. Pregnant mothers join search for causes of autism
4. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
5. Innovative research technique reveals another natural wonder in Yellowstone Park
6. Mother-of-pearl -- Classic beauty and remarkable strength
7. The fisherman is a predator like any other
8. Nanoparticles carry chemotherapy drug deeper into solid tumors
9. A faster way to recover from chemotherapy and marrow transplant
10. Another sexual attraction is possible ...
11. Study suggests other causes for childhood brain aneurysms

Post Your Comments:
(Date:7/27/2014)... Microorganisms like bacteria and fungi can evade treatment by ... antifungal drugs. These permanent mutations were once thought to ... Now a new study has shown that microorganisms can ... as epimutations -- to gain the benefits of drug ... was discovered in a fungus called Mucor circinelloides, it ...
(Date:7/27/2014)... Cancer Institute have found that targeting a molecule in ... according to research published in Nature today ... Queen Mary University of London, have found that a ... to repair itself after chemotherapy or radiotherapy, which kill ... FAK from blood vessels that grew in melanoma or ...
(Date:7/27/2014)... data from over 18,000 patients, scientists have identified ... in Parkinson,s disease, including six that had not ... Nature Genetics , was partially funded by the ... scientists working in NIH laboratories. , "Unraveling the ... the multiple mechanisms involved in this complex disease, ...
Breaking Biology News(10 mins):Scientists discover new, noncommittal mechanism of drug resistance 2Scientists discover new, noncommittal mechanism of drug resistance 3New drug target can break down cancer's barrier against treatment 2NIH scientists find 6 new genetic risk factors for Parkinson's 2
(Date:7/25/2014)... (PRWEB) July 25, 2014 According to ... "Biological Drugs Market - Global Industry Analysis, Size, Share, ... biological drugs market is estimated at USD 161,056.5 million ... CAGR of 10.1% from 2014 to 2020, to reach ... , The biological drugs market is witnessing a significant ...
(Date:7/25/2014)... , July 25, 2014  Galmed Pharmaceuticals Ltd. (Nasdaq: ... focused on the development and commercialization of a once-daily, ... cholesterol gallstones, today announced financial results for the period ... Financial Summary: , Reported cash and cash equivalents ... $137,000 at December 31, 2013.  , Reported a ...
(Date:7/24/2014)... 2014 -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the "Company") announced ... control Phase 3 study of Zerenex (ferric citrate), the ... treatment of hyperphosphatemia in patients with end-stage renal disease ... iRon delivery with FErric CiTrate in EsrD) was published ... Society of Nephrology ( JASN ). ...
(Date:7/24/2014)... Calif. , July 24, 2014  Asterias ... in the emerging field of regenerative medicine, announced ... of a presentation to investors on Tuesday, July ... PDT.  The presentation will include an overview of ... access the webcast, visit http://www.ustream.tv/channel/asterias-biotherapeutics at ...
Breaking Biology Technology:Biological Drugs Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 2Biological Drugs Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 3Galmed Pharmaceuticals Reports First Half 2014 Financial Results 2Galmed Pharmaceuticals Reports First Half 2014 Financial Results 3Galmed Pharmaceuticals Reports First Half 2014 Financial Results 4Galmed Pharmaceuticals Reports First Half 2014 Financial Results 5Galmed Pharmaceuticals Reports First Half 2014 Financial Results 6Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 4Asterias Biotherapeutics Announces Live Investor Webcast 2Asterias Biotherapeutics Announces Live Investor Webcast 3Asterias Biotherapeutics Announces Live Investor Webcast 4
Cached News: